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In their excellent review of dosing continuous renal 
replacement therapy (CRRT), Dr Prowle and colleagues 
concluded that patients should be prescribed 20 to 
25 ml/kg/h [1]. However, by averaging CRRT dose over 
time, studies in this area obfuscate the beneﬁ  ts of appro-
priately higher dose therapy early in the course of illness, 
potentially misguiding clinicians into blindly adopting a 
‘one-size-ﬁ  ts-all’ approach and consequently prescribing 
inadequate doses in life-threatening emergencies. To take 
a crude example, it would be inappropriate to prescribe 
20 ml/kg/h CRRT in a patient with serum potassium 
9  mmol/L. Rather, the highest possible dose of CRRT 
should be initially prescribed to maximize solute 
clearance. Th  is depends on the maximum circuit ﬂ  ow 
permitted by the access catheter, which in turn deter-
mines the maximum dose, assuming that the 
counter current  ﬂ  ow to blood ﬂ  ow ratio should be <0.3 
with diﬀ   usive CRRT, or a ﬁ   ltration fraction with 
convective therapy <0.2 [2]. As the potassium level falls, 
the dose can be lowered to more conventional levels.
Parallels could be drawn to general anaesthesia, where 
induction and maintenance are two distinct phases with 
diﬀ  erent requirements. CRRT prescription could simi  lar  ly 
be conceptualized as ‘induction’, where life-threatening 
abnor  malities are corrected quickly with high-dose therapy, 
then ‘maintenance’ where solute clearance is achieved with 
more temperate doses (for example, 20 to 25 ml/kg/h) to 
avoid complications such as hypo  phos  phataemia.
It seems unlikely that this issue will be the subject of 
prospective research. Yet the principle that faster correc-
tion of life-threatening abnormalities leads to better 
patient outcomes seems both practical and intuitive.
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We thank Dr MacLaren for his comments. We agree that 
such ‘induction’ therapy is mandatory in situations of 
severe hyperkalemia (>8.0 mmol), especially when on-
going potassium release is taking place (for example, 
rhabdomyolysis). Although such reasoning and thera-
peutic adjustment seemed obvious to us, we agree that 
making them explicit is important.
We would also like to emphasize several important 
aspects of adjustments to unique cases. First, avoidance 
of often ineﬀ  ective and delayed interventions in critically 
ill patients with severe acute kidney injury [3] and early 
CRRT as applied in the RENAL (Randomised Evaluation 
of Normal versus Augmented Level of Replacement 
Th  erapy) trial [4-6] are key to preventing such life-
threaten  ing events in the ﬁ  rst place. In this regard, in the 
RENAL trial, only 6 out of 1,454 (0.4%) patients with 
baseline electrolyte values had a potassium level 
>8  mmol/L. Second, faster solute removal can be 
achieved by the application of modiﬁ   ed dialytic tech-
niques that deliver full equilibration between plasma ﬂ  ow 
and dialysate ﬂ  ow and much greater solute clearance [7]. 
Th  ird, the concept of ‘induction’ applies to volume 
control as well: in a patient with pulmonary edema or 
receiving large amounts of blood products, the intensity 
of volume removal should be adjusted accordingly. 
Finally, however, also a word a caution: in the RENAL 
trial, three patients suﬀ   ered from disequilibrium syn-
drome because of too rapid solute removal. In patients 
with very high concentrations of azotemic markers, 
overly intensive solute removal can be detrimental. 
Similarly, in patients with marked hyper- or 
hyponatremia, rapid normali  zation can be dangerous and 
induce cerebral edema or demyelination.
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© 2011 BioMed Central LtdIn the end, for RRT as well as every other medical 
therapy, there is no substitute for a trained, educated, 
committed, diligent and thoughtful physician.
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